Celldex Therapeutics, Inc. (CLDX)
28.25
-1.68
(-5.61%)
USD |
NASDAQ |
Nov 05, 16:00
27.87
-0.38
(-1.35%)
After-Hours: 20:00
Celldex Therapeutics Enterprise Value : 1.643B for Nov. 4, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2026 | 1.643B |
| November 03, 2026 | 1.626B |
| November 02, 2026 | 1.573B |
| October 30, 2026 | 1.656B |
| October 29, 2026 | 1.640B |
| October 28, 2026 | 1.622B |
| October 27, 2026 | 1.660B |
| October 26, 2026 | 1.609B |
| October 23, 2026 | 1.590B |
| October 22, 2026 | 1.568B |
| October 21, 2026 | 1.599B |
| October 20, 2026 | 1.671B |
| October 19, 2026 | 1.623B |
| October 16, 2026 | 1.455B |
| October 15, 2026 | 1.565B |
| October 14, 2026 | 1.479B |
| October 13, 2026 | 1.511B |
| October 12, 2026 | 1.604B |
| October 09, 2026 | 1.640B |
| October 08, 2026 | 1.594B |
| October 07, 2026 | 1.682B |
| October 06, 2026 | 1.728B |
| October 05, 2026 | 1.852B |
| October 02, 2026 | 1.778B |
| October 01, 2026 | 1.820B |
| Date | Value |
|---|---|
| September 30, 2026 | 1.838B |
| September 29, 2026 | 1.777B |
| September 28, 2026 | 1.766B |
| September 25, 2026 | 1.735B |
| September 24, 2026 | 1.765B |
| September 23, 2026 | 1.737B |
| September 22, 2026 | 1.924B |
| September 21, 2026 | 2.268B |
| September 18, 2026 | 2.295B |
| September 17, 2026 | 2.354B |
| September 16, 2026 | 2.332B |
| September 15, 2026 | 2.317B |
| September 14, 2026 | 2.369B |
| September 11, 2026 | 2.190B |
| September 10, 2026 | 2.284B |
| September 09, 2026 | 2.338B |
| September 08, 2026 | 2.365B |
| September 04, 2026 | 2.409B |
| September 03, 2026 | 2.384B |
| September 02, 2026 | 2.393B |
| September 01, 2026 | 2.374B |
| August 31, 2026 | 2.405B |
| August 28, 2026 | 2.365B |
| August 27, 2026 | 2.470B |
| August 26, 2026 | 2.478B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.813B |
| Alnylam Pharmaceuticals, Inc. | 20.97B |
| Anika Therapeutics, Inc. | 259.85M |
| Savara, Inc. | 814.53M |
| Vericel Corp. | 2.259B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -73.50M |
| Revenue (Quarterly) | 0.022M |
| Total Expenses (Quarterly) | 73.52M |
| EPS Diluted (Quarterly) | -0.9443 |
| Gross Profit Margin (Quarterly) | -4.00K% |
| Profit Margin (Quarterly) | -334.1K% |
| Earnings Yield | -15.43% |
| Normalized Earnings Yield | -15.43 |